Bi Xin'an-B Early Rally Surpasses 15% Yesterday's Close Rises Over 50% Renal Denervation (RDN) Enters US Hypertension Guidelines

Bi Xin'an-B (02185) rallied in the early market, rising over 15% at one point and hitting a new high of HKD 10.77, surpassing its near-two-year high yesterday, with a gain of over 50%. As of this writing, the stock price has risen 7.63%, currently trading at HKD 10.01, with a turnover of HKD 611.708 million.

Recently, the American Heart Association (AHA), the American College of Cardiology (ACC), and other organizations jointly published new guidelines for the prevention, detection, assessment, and management of hypertension in adults. The updated guidelines build on the 2017 edition, with updates to diagnosis, risk assessment, and treatment in various aspects, aiming to provide more precise guidance for clinical practice and reduce cardiovascular disease (CVD) risks. Among the updates is the addition of renal denervation (RDN) as a recommended therapeutic approach.

Another noteworthy point is that previously, there were reports indicating that the US Centers for Medicare & Medicaid Services (CMS) released a new RDN insurance proposal. The proposal suggests including RDN in the coverage scope for patients with uncontrolled hypertension. The proposal has initiated a 30-day public review period, with the final decision expected to be announced by October 8, 2025, or earlier.